JH
Insider
James Huang
DirectorJames Huang (Director) filed 4 Form 4 reports in the trailing twelve months (2 purchases, 2 sales), most often in Atara Biotherapeutics, Inc. (ATRA). Across 2 priced purchase filings, the average 21-session return was -4.9% from execution and -2.5% from disclosure (delay-adjusted; derived). The largest single filing was $4.0M of CNTB (1,160,000 sh × $3.45, as filed), executed Mar 31.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-4.9%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-2.5%
same 2 filings, from disclosure
Filings, ttm
4
2 buys · 2 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.0M
shares × price, as filed
Last traded
May 29
Filed Jun 2
Median ADV $642K across their filed names
Open performance→Volume by month
Buys $5.2M
Sells $3.7M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
4 filings
Sector per market data · by filing · past 12 months
Most traded names
ATRARecent filings
CNTBPURCHASE
Connect Biopharma Holdings Limited
View filing →
$372K150,000 sh × $2.48
Exec May 29
Filed Jun 2 · 4:30 PM ET ATRASALE Atara Biotherapeutics, Inc. View filing → $3.2M
313,446 sh × $10.10
Exec May 7
Filed May 11 · 5:30 PM ET CNTBPURCHASE Connect Biopharma Holdings Limited View filing → $4.0M
1,160,000 sh × $3.45
Exec Mar 31
Filed Apr 1 · 4:30 PM ET ATRASALE Atara Biotherapeutics, Inc. View filing → $489K
80,554 sh × $6.07
Exec Jan 12
Filed Jan 14 · 5:30 PM ET ATRAPURCHASE Atara Biotherapeutics, Inc. View filing → $670K
55,000 sh × $12.19
Exec Aug 15 2025
Filed Aug 19 2025 · 8:15 PM ET ATRAPURCHASE Atara Biotherapeutics, Inc. View filing → $186K
19,335 sh × $9.64
Exec Jul 17 2025
Filed Jul 21 2025 · 9:00 AM ET